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ABBREVIATIONS 
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IVF    In Vitro Fertilisation 
ART    Assisted Reproductive Techniques 
ICSI    Intracytoplasmic Sperm Injection 
ROS    Reactive Oxygen Species 
IL-6    Interleukin 6 
IVD    In Vivo Development  
GIFT    Gamete Intra-Fallopian Transfer 
ZIFT     Zygote Intra-Fallopian Transfer 
WOI    Window of Implantation  
IUD    Intrauterine Device 
ER    Estrogen Receptor 
PR    Progesterone Receptor 
PRA    Progesterone Receptor Isoform A 
PRB    Progesterone Receptor Isoform B 
AF    Activation Factor 
DNA    Deoxyribonucleic Acid 
cDNA Complementary DNA synthesized from a 
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messenger RNA (mRNA) template in a reaction 
catalyzed by the enzyme reverse transcriptase 
and the enzyme DNA polymerase 
RNA    Ribonucleic Acid 
mRNA   Messenger RNA 
mPR    Membrane Progesterone Receptor 
miRNA   micro RNA 
GPCRs   G-protein-coupled receptors 
PAQR    AdipoQ Receptor 
IHC    Immunohistochemistry 
LIF    Leukaemia Inhibitory Factor 
LIF-R    Leukaemia Inhibitory Factor Receptor 
LEPR    Leptin Receptor 
PCR    Polymerase Chain Reaction 
RT-PCR   Reverse transcriptase PCR 
EECs    Endometrial Epithelial Cells 
ESC    Endometrial Stromal Cells 
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PKs/PROKs  Prokineticins 
EG-VEGF Endocrine Gland-Derived Vascular Endothelial 
Growth Factor 
PCOS  Polycystic Ovarian Syndrome 
Bv8    Bombina variegata 8 
PROK-R1   Prokineticin Receptor 1 
PROK-R2   Prokineticin Receptor 2 
IP3    Inositol Phosphate 3 
COX    Cyclooxygenase 
hCG    Human Chorionic Gonadotropin 
DKK1   Dickkopf 1 
WNT Family of Signalling Secreted Lipid-Modified 
Proteins. The origin of the name Wnt comes 
from a hybrid of Int and Wg (wingless) in 
Drosophila, which is the best characterized 
Wnt gene 
FSH    Follicle Stimulating Hormone 
rFSH    Recombinant Follicle Stimulating Hormone 
  10 
LH    Luteinising Hormone 
GnRH   Gonadotrophin-Releasing Hormone 
OCP    Oral Contraceptive Pill 
CO2    Carbon Dioxide 
DAVID  Database for Annotation, Visualization and 
 Integrated Discovery 
STRING Search Tool for the Retrieval of Interacting 
Genes/Proteins 
PCA    Principal Component Analysis 
NSAIDs   Non-Steroidal Anti-Inflammatory Drugs 
ABC Avidin - Biotin Immunohistochemistry Method 
Ig    Immunoglobulin 
LSAB    Labelled Streptavidin-Biotin 
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Since Louise Brown, the first IVF (in vitro fertilisation) baby born in 
1978 [1], assisted reproductive techniques (ARTs) have become 
commonplace. It is estimated that 1-4% of the population in developed 
countries was conceived using this technology [2]. In 2008 alone, 
148,055 ART cycles were performed in 436 reporting clinics in the USA, 
resulting in 46,326 live births, corresponding to over 1% of all infants born 
in the USA [3]. According to the European Society of Human Reproduction 
and Embryology (ESHRE), within Europe, the countries with the most 
reported ART cycles were France (66,000), Germany (55,000), Spain (50,000), 
the UK (44,000) and Italy (41,000). In Spain, 106 out of 160 clinics reported 
a total of 55,134 cycles of IVF/ICSI in 2009 [4] and the largest number of egg 
donation cycles of any country in Europe [5].  
2.1 “In Vitro” EMBRYO DEVELOPMENT 
Knowledge about embryonic development inside (in vivo) and outside 
(in vitro) the physiological environment of the reproductive tract and 
endometrial receptivity is increasing. However, more research is needed on 
several topics, such as the dialogue between the embryo and endometrium, 
early embryo development and a wide variety of relevant actions that are 
required to accomplish the objective of every infertility treatment: a healthy 
baby.  
Preimplantational development is a process involving many important 
steps, such as oocyte maturation, cleavage divisions, embryonic genome 
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activation, compactation, blastocyst formation, expansion, hatching and 
implantation into the endometrium [6]. 
A receptive endometrium is mandatory for implantation to occur [7], 
and embryonic implantation has classically been divided into three 
consecutive phases: apposition, adhesion and invasion. During apposition, 
the human blastocysts find a specific area in the maternal endometrium in 
which to implant. In the adhesion phase, which occurs 6-7 days after 
ovulation within the “implantation window”, direct contact occurs between 
the endometrial epithelium and the trophectoderm. Finally, in the invasion 
phase, the embryonic trophoblast traverses the basement membrane, passes 
the endometrial stroma and reaches the uterine vessels [8]. Successful 
implantation requires both synchronous embryonic development and an 
interaction between blastocyst and endometrium. Regulation of molecules 
such as the integrins promotes blastocyst adhesion [9]. The molecular 
mechanisms regulating embryo implantation have been studied using 
decidualization and knock-out (KO) mouse models identifying genes that are 
functionally involved in endometrial receptivity. 
In ARTs, fertilisation occurs outside of the Fallopian tube, and the 
preimplantation embryos are cultured in vitro before being transferred into 
the uterus. Therefore, embryo quality varies widely both between and within 
patients.  
The embryo is able to develop in the in vitro culture medium and has 
the ability to adapt to environment changes to a certain extent. If 
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environmental changes exceed this capacity to adapt, abnormal embryonic 
development may result [10]. 
The effect of culture conditions on the embryonic epigenetic program 
has been investigated in the mouse model by comparing the imprinting 
status of in vivo versus in vitro cultured embryos using five different 
commercial media [11]. Embryos were analysed for H19, Snrpn and Peg3, 
demonstrating that in vivo-derived embryos were superior to all five culture 
systems in terms of genomic imprinting.  
However, a related study did not find significant differences between in 
vivo and in vitro developed blastocysts [12]. In contrast to the Market-Velker 
study, in which pools of five blastocysts were used for the imprinted 
methylation analysis, this team derived stem cells (ES) from both in vivo and 
in vitro embryos. They observed that in vitro stem cells had increased 
abnormal genomic imprinting compared with in vivo stem cells, but only at 
early passages [12]. At later passages, they did not observe significant 
differences.  
New developments give us some information about the incorporation of 
specific amino acids into the medium to prevent metabolic changes [13] and 
to favour the development of a new generation of sequential embryo culture 
media that have dramatically increased the ART success rate [14], except in 
aging patients [15]. 
Non-invasive methods have been developed as alternatives to 
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aneuploidy screening, such as metabolic profiling based on the analysis of 
embryo culture media [16]. In this approach, the comparison of the 
aneuploidy levels of six chromosomes related to early pregnancy loss with 
the amino acid metabolism profile of day 2 to 5 embryos demonstrated that 
abnormal embryos presented altered amino acid turnover in vitro compared 
with their normal counterparts [17]. 
A frequent feature of in vitro culture is that cleaved embryos arrest 
their development at the 2- to 4-cell stage [18]. A great deal of research has 
attempted to elucidate possible causes and mechanisms of this 
phenomenon. Embryos cultured in 20% oxygen conditions display 
significantly elevated levels of intracellular reactive oxygen species (ROS) and 
higher frequencies of permanent embryo arrest compared with the embryos 
produced under 5% oxygen atmospheres [19]. Although this finding seems to 
imply that low-oxygen and antioxidant treatments can improve embryo 
development, the problem of oxidative stress is far more complicated (for 
review, see Betts and Madan in 2008 [20]).  
Embryologists have always used morphological criteria to identify the 
most viable embryo [21]. New strategies being explored include proteomic 
and metabolomic profiling [22, 23], birefringence imaging [24], oxygen 
consumption [25] and time-lapse imaging [26]. Another tool for embryo 
selection is to examine the oxidative status of the embryo [27].  
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Co-culture system 
To enhance in vitro development, embryos have been cultured in the 
presence of nursing cell types, developing coculture systems. In 1965, Cole 
and Paul managed to co-culture mouse embryos with irradiated HeLa cells 
[28]. Later, Allen and Wright co-cultured porcine embryos at various stages 
of development on porcine endometrial cell monolayers [29]. Since then, this 
strategy has been used in bovine [30] and human embryos [31] at the clinical 
level to improve blastocyst number and quality in patients who have suffered 
implantation failure in an oocyte donation program, but not in IVF patients 
[32]. The five-year (1997-2001) clinical experience in blastocyst transfer 
cultured on heterologous endometrial epithelial cells as co-culture systems 
in our group revealed an increase of blastocyst formation rates and an 
improvement in implantation and pregnancy rates [33].  
Non-invasive diagnosis 
The secretome profile of implanted blastocysts grown in sequential 
versus endometrial epithelial cell co-culture systems has been analysed, 
demonstrating that more IL-6 was consumed in the media of viable embryos 
compared with blastocysts that did not implant. This finding supports the 
idea that IL-6 could be important for embryo development and viability [34].  
Currently, there is a trend to optimise costs/benefits by going back to 
more physiological treatments. The use of mild ovarian stimulation [35] and 
single embryo transfer [36] are just two examples. In vivo embryo culture is 
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another option that would also contribute to advancing the state of the art.  
Thus, developing new in vivo embryo development techniques without 
disrupting the embryo-endometrial dialogue would be of great interest for the 
future of ART.  
2.2 “In vivo” EMBRYO DEVELOPMENT 
An in vivo culture system exists inside the uterine cavity in an in vivo 
development (IVD) system. IVD is a wise alternative to the in vitro culture 
system, with the expected physiological merits of a natural 
microenvironment. The use of cell encapsulation allows control of the culture 
duration and convenient retrieval of embryos for diagnosis prior to leaving 
them to implant within the uterine endometrial wall.  
The medical device developed by ANECOVA SA (product family: 
Anecova-d1; Device reference: ACVd1) has been classified as Class II by the 
notified body (CE Mark). This device consists of three main parts: the capsule 
(vessel for the gametes), the connection system (stabilisation) and the 
retrieval string. 
 A first prototype was used in the present clinical investigation to 
demonstrate that the device was capable of being introduced through the 
cervix, immobilised at the desired location for a specific period of time (up to 
6 days) and retrieved easily. 
To ensure relevant biocompatibility of this device towards the gametes 
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(oocytes, sperm) and embryos, Anecova carried out an in vitro toxicity test 
using mouse and bovine embryos. The results of these tests provided 
evidence that the components and materials used in the device were non-
toxic for bovine embryos and biologically neutral in terms of fertilisation and 
embryonic development.  
This study also provided evidence that the device could be safely and 
accurately loaded and unloaded with bovine embryos that have an equivalent 
size to human embryos at the same development stage. Moreover, every 
material and the device itself were tested in vitro using a mouse embryo 
model. 
2.3 ENDOMETRIAL RECEPTIVITY 
The endometrial tissue consists of an inner lumen that is lined with an 
epithelial cell layer from which emerge glandular structures that are also 
lined by epithelial cells. Glands produce embryonic factors that are essential 
for the embryo to attach and invade the stromal compartment to establish 
the pregnancy.   
Endometrial receptivity is acquired during a short period of time in the 
mid-luteal phase referred to as the window of implantation (WOI) defined by 
timing to the LH surge. During this period of time (LH+7 to LH+9), the 
endometrial epithelium acquires a functional ability to support blastocyst 
adhesion [37]. Stromal cells differentiate into decidual cells after LH-9 to 
support trophoblast invasion and placental development. 
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To explain the basic mechanisms implicated in endometrial receptivity, 
researchers have investigated the morphological changes and modifications 
of the plasma membrane [38] and cytoskeleton [39] using histology, electron 
microscopy, molecular biology and biochemistry in animal models and 
humans.  
In the pregenomic era, the single-molecule approach was a useful way 
to investigate candidates for endometrial receptivity. Among the main factors 
identified are leukaemia inhibitory factor (LIF), leptin and integrins, although 
none of them has proven to be clinically useful as biomarkers [40]. 
Leptin is an adipocyte-specific hormone that regulates adipose-tissue 
mass through hypothalamic effects on satiety and energy expenditure, acting 
through the leptin receptor (LEPR), a single-transmembrane-domain receptor 
of the cytokine receptor family [41]. Depending on the intracytoplasmic 
domains, at least six leptin receptor isoforms (Ob-Ra, b, c, d, e, and f) have 
been described from different RNA splicing [42]. Ob-R knockout mice are 
obese and infertile, and this phenotype can be restored by exogenous leptin 
treatment, but not by food restriction [43]. Leptin and OB-Rt mRNA has been 
identified in human oocytes and preimplantation embryos at different stages 
(oocyte metaphase II, two-cell, four-cell, eight-cell, morula, expanded 
blastocyst and hatched blastocyst) [44] and in the human endometrium [45].  
LIF binds to a heterodimeric receptor that consists of two 
transmembrane proteins: LIF receptor (LIF-R) and gp130 [46], a common 
receptor for IL-6 family cytokines. LIF-knockout mice are infertile 
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because of the lack of embryonic adhesion, which can be restored by 
exogenous LIF. LIF-/- embryos implant normally in the uteri of wild-type 
recipients, indicating the importance of this cytokine for mouse implantation 
[47]. 
A crucial process in the cyclical tissue regeneration and growth of the 
normal endometrium is angiogenesis regulated in part by prokineticins (PKs). 
PKs are a recently discovered family of angiogenic factors [48] formed by 
PK1/PROK-1, also known as endocrine gland-derived vascular endothelial 
growth factor (EG-VEGF), and PK2/PROK-2, also known as Bv8 (Bombina 
variegata 8). 
PROK-1 induces proliferation, migration, and fenestration in capillary 
endothelial cells. Its expression is similar to VEGF, induced by hypoxia and 
restricted to steroidogenic organs (ovary, testis, adrenal, and placenta). 
PROK-2 expression shows a similar distribution, but with stronger 
expression in the testis and leukocytes [49, 50].   
Prokineticins bind to two closely related G-protein coupled receptors, 
known as prokineticin receptor 1 (PROK-R1) and prokineticin receptor 2 
(PROK-R2), both of which are able to bind PROK-1 and PROK-2 with similar 
affinities [51].  
In the human endometrium, the expression of PROK-1 and its receptor 
has been reported using quantitative RT-PCR. Furthermore, PROK-1 and 
PROK-2 were localised by immunohistochemistry and in situ hybridisation to 
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various endometrial components [52] with high expression of PROK-1 in the 
secretory phase while PROK-2 is quite stable.  
Evans’ team elucidated the manner in which the interaction between 
PROK-1 and PROK-R1 regulates the expression of other factors related to 
decidual response, such as COX-2. This factor is a key regulator of 
prostaglandin synthesis. Substantial evidence has suggested that COX-2 is 
expressed in cells that are known to participate in inflammatory conditions 
[53]. Evans and colleagues reported that PROK-R1 and COX-2 colocalise to 
glandular epithelial and stromal cells of mid-secretory endometrium and 
first-trimester decidua. According to their results, PROK-1 may have a great 
ability to regulate COX-2 expression in both compartments during 
endometrial receptivity and early pregnancy. A new signalling pathway 
triggered by hCG has been suggested that induces both PROK-1 and LIF 
expression and mediates maternal-embryonic crosstalk [54]. Recent 
publications have found a correlation between genetic polymorphisms in 
PROK-1 and PROK-R1 and recurrent miscarriage [55] and have also 
associated a defective decidualization process and recurrent miscarriage with 
an aberrant elevation in PROK-1 expression [56]. 
PROK-1 and Dickkopf 1 (DKK1) have been investigated during the 
period of endometrial receptivity and early pregnancy, demonstrating that 
both genes regulate endometrial actions, such as epithelial cellular 
proliferation and differentiation of the stroma during early pregnancy [57]. 
DKK1 is a secreted protein with two cysteine-rich regions and is involved in 
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embryonic development through the inhibition of the WNT signalling 
pathway.  
In the genomic era, numerous studies have investigated the gene 
expression profile of the human endometrium [58]. These analyses have 
generated long lists of candidate endometrial receptivity genes [59]. 
Accumulated evidence indicates the presence and function of estrogen and 
progesterone receptors in stromal and epithelial compartments [60, 61]. The 
estrogen receptors (ER) are found in all endometrial cell types, whereas 
progesterone receptor (PR) expression varies depending on the cell type and 
phase of the ovarian cycle. 
The actions of steroid receptors are clearly influenced by specific 
coactivators and corepressors that mediate steroid hormone action. Lessey 
and collaborators suggested that the overexpression of one or more p160 
coactivators induces the endometrium to become more sensitive to estrogen 
and that such overexpression may thus account for the higher incidence of 
endometrial abnormalities seen in women with PCOS [62]. 
Progesterone plays a crucial role in the reproductive process associated 
with the initiation and maintenance of pregnancy. Many genes that are 
regulated and affected by progesterone are likely to be involved in both 
activation and repression during the secretory phase.  
PR, a member of the steroid receptor superfamily, mediates the 
physiological effects of progesterone. Some research on selective 
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progesterone receptor modulators has demonstrated that the mechanisms of 
action and the effects of these receptors on tissues of the reproductive 
system have potential efficacy for gynaecologic indications [63].  
The published research prompted us to support the idea that PR is 
critical for embryo implantation [64]. The PR gene uses separated (ER)-
inducible promoters and translational start sites to produce two different 
isoforms, PRA and PRB, which are identical except for an additional string of 
165 amino acids that is present only in the N terminus of PRB [65]. This 
region, which is unique to PRB, contains a third transcription activation 
factor (AF3) in addition to the two other activation factors, AF1 and AF2, that 
are common to both PRA and PRB [66]. 
 
Figure 1: Scheme of PRA and PRB promoters. There are two alternative transcription 
starting sites (PRB TSS and PRA TSS). Two alternative translational initiation sites for 
PRB and PRA are shown as AUG1 and AUG2, respectively. DBD: DNA binding domain; 
H: hinge domain; and LBD: ligand binding domain. AF1, AF2 and AF3 are transcription 
activation factors.  
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Progesterone crosses the nuclear membrane to bind directly to PR 
located in the nucleus. The activated PR moves into nuclear aggregates, or 
'foci', whereas unbounded PR is distributed evenly throughout the nucleus 
[67]. In human tissues, ligand-dependent dimerisation between PRA and PRB 
is required to form the functional transcription factor unit on DNA. 
Although PRA and PRB are distinct transcription factors that mediate 
different responsive genes and physiological effects, they share several 
structural domains. PRB is considered a strong activator of transcription of 
several PR-dependent promoters in a variety of cell types in which PRA is 
inactive. 
Both PRA and PRB are stimulated in the human endometrium by the 
presence of estrogen during the follicular phase, and their expressions are 
maximal around ovulation. On the contrary, PR expression diminishes as the 
P levels increase during the secretory phase [68]. 
Although the in vivo evidence is very weak, several transfection 
experiments have shown that PRA can act as a dominant negative inhibitor 
of PRB, dependent upon cell type and promoter context [69]. Moreover, PRA, 
but not PRB, is critical for endometrial function, including embryo 
implantation and decidualisation, in PR knockout mice [70].  
The binding of P results in the formation of active PR homodimers and 
heterodimers between receptor isoforms. Conneely and colleagues published 
a study in which they generated a PRB knockout model [71], confirming that 
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selective activation of PRA by progestin agonists is sufficient to mediate the 
ovulatory activities of progesterone and that heterodimer interaction with 
PRB is not required for this event. However, the disruption of the normal 
expression pattern of PRA may lead to aberrant regulation of proliferative 
target genes in the mammary gland. These researchers suggested that 
selective activation of PRA using isoform-selective agonists could have a 
protective effect against both uterine and mammary gland hyperplasias.  
Both investigations suggested that PRA is the predominant isoform 
expressed in the female reproductive tract and mammary glands in the 
mouse. However, the results cannot be straightforwardly extrapolated to 
humans.  
In human endometrium, PRA and PRB have been co-localised by single 
cell analysis [72]. There is homogeneous expression of the two isoforms in 
the nuclei within the same tissue compartment during most of the phases of 
the menstrual cycle, with some exceptions. A predominance of PRB exists in 
the glands in the mid-secretory phase of the cycle, suggesting that estrogen 
binding to ER in the glands may cause this increase. In the secretory phase, 
the dynamics of PRB in the stroma were similar to those described in the 
glands, except that the magnitude of the changes was less pronounced. 
Thus, the discordance of progesterone down-regulation of these 
receptors in the glandular epithelium suggests differential sensitivities of the 
two isoforms to the effects of progesterone during the secretory phase.  
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PRs distribute into specific nuclear foci under hormonal control in 
normal human endometrium during the menstrual cycle [67]. Both receptors 
were less evenly distributed and localised in discrete subnuclear foci during 
the mid-secretory phase compared with the proliferative phase and early 
secretory phase. Researchers also showed an increase in the number of PRB 
into nuclear foci compared with PRA at all stages of the menstrual cycle. This 
finding suggests that PRB may have more transcriptional activity than PRA. 
Mote’s [72] data on the predominance of PRB expression in the glandular 
epithelium during the mid-secretory phase, combined with the findings in 
this study, suggest that PRB could be the principal mediator in the human 
uterus. 
Given that PRA and PRB are expressed in most human tissues, 
variations in the expression levels of specific PR co-regulators, which have 
different affinities for the PR, likely support a mechanism by which a 
functional prevalence of PRA and PRB is managed.  
Although these nuclear receptors mediate the majority of 
progesterone’s actions, other progesterone receptors situated in the cell 
membrane have been documented in teleost fish [73] and subsequently in 
mammals [74]. These receptors are a potential mediator of non-traditional 
progestin actions, particularly in tissues where PR is absent. There are three 
membrane-PR gene isoforms, mPRα (PAQR VII), mPRβ (PAQR VIII), and mPRγ 
(PAQR V), whose mechanism of action begins quickly with the binding of the 
progestin, the activation of G proteins and their downstream signalling 
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pathways.  
Two additional related proteins named mPRδ and mPRε have also been 
shown to bind progesterone. These receptors have no apparent homologies 
with known G-protein-coupled receptors (GPCRs) or nuclear progesterone 
receptors. They belong to the adiponectin receptors of the progesterone and 
adipoQ receptor (PAQR) family [75]. MPR isoforms’ functionality has been 
implicated in oocyte growth [76], transport [77] and the preparation of the 
uterus for implantation, gestation, foetal development [78] and parturition 
[79]. 
IUDs 
IUDs represent one of the most effective contraception methods 
because they induce changes causing endometrial refractoriness that 
prevent embryonic implantation [80]. The forerunners of the modern IUD 
were small stem pessaries used in the 1800s: small button-like structures 
that covered the opening of the cervix and were attached to stems extending 
into the cervical canal [81]. 
In 1902, a device that extended into the uterine cavity was developed 
by Hollweg in Germany and used for contraception. It was sold for self-
insertion, but the risk of infection was great, earning the condemnation of 
the medical community [82].  
Surprisingly, doctors did not begin to understand and use IUDs until 
the 1960s. The foreign body, now made of metal or plastic, is treated 
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as a foreign element and is attacked by the immune system. In the 1960s 
and 1970s, a plethora of types were introduced. The devices developed were 
made of plastic (polyethylene) impregnated with barium sulphate so that 
they would be visible on an x-ray, such as the Lippes Loop, which quickly 
became the most widely prescribed IUD in the United States in the 1970s 
[83]. 
The addition of copper to the IUD was proposed by Zipprt, whose 
experiments with metals indicated that copper had local effects in the 
endometrium [84]. Studies also indicate that copper acts as a spermicide and 
could reduce the motility of spermatozoids and their capacity to fertilise [85]. 
The copper IUD is associated with an inflammatory response marked by an 
influx of polymorphonuclear leukocytes, mast cells and macrophages [86]. It 
has been postulated that this inflammatory process creates an unsuitable 
environment for the embryo.  
The impact of IUDs on endometrial molecules such as integrins at the 
time of implantation in fertile women has been demonstrated [87]. Moreover, 
a differential expression pattern of HOXA10 has been documented in 
response to copper-IUD use [88].  
Our group has investigated the effect of an inert intrauterine device on 
the endometrial gene expression profile using microarray technology. The 
majority of genes altered during the refractory endometrium remained 
dysregulated two months after IUD removal. However, one year later, most of 
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them returned to a normal level of gene expression [89]. 
This evidence demonstrated the importance of investigating whether 
the Anecova device induces an endometrial refractory alteration in genomic 
or proteomic terms similar to those exerted by common IUDs.  
 
 
  30 
 
 
 
 
 
 
 
3. OBJECTIVE 
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The present work was conducted at the IVI Valencia and at the 
Queen’s Medical Research Institute in Edinburgh to investigate whether the 
Anecova device inserted in the lower segment of the endometrial cavity 
affects endometrial receptivity.  
The first objective of the study was to evaluate the clinical impact of 
this IVD system in the maternal endometrium. For this purpose, we tested 
the endometrial effects of an unloaded device (i.e., the capsule was not 
loaded with gametes or embryos) for a period of up to 6 days. The evaluation 
was focused on verifying device tolerance by a daily clinical evaluation and 
direct observation through hysteroscopy after the device’s retrieval.  
The second aim was to evaluate whether the presence of the device 
causes any change in the endometrial receptivity genomic profile. For this 
reason, using a wide genomic approach, we analysed the gene expression 
profile of the endometrium obtained at day hCG+7 from ovum donors 
undergoing IVF in whom this device was inserted for one, three or five days 
compared with the same woman’s endometrium without the device. Gene 
expression changes induced by an inert IUD were used as a control.  
 
Both studies were conducted in accordance with the requirements of 
European Standard EN 540 (1993). 
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4. MATERIALS AND 
METHODS 
  33 
4.1PATIENTS, INFORMED CONSENT AND 
INSTITUTIONAL REVIEW BOARD APPROVAL 
The study was carried out at the Instituto Valenciano de Infertilidad 
(IVI), Valencia (Spain). Patients from the IVI ovum donation programme 
volunteered to participate in this clinical study. They were informed about 
their participation in this project and signed an informed consent form. This 
study was financed by Anecova and was approved by the IVI’s Ethical 
Committee on July 29, 2004. The research number for this clinical trial is 
NCVPTRV1.  
4.2 MEDICAL DEVICE 
Two different prototypes of a new intrauterine device were developed by 
Anecova (ANECOVA S.A., Geneva, Switzerland) and used for this project.  
Model “F”:  ACVd1-F is used as a product reference for devices without 
stabilisation. We used this model for the study of clinical security and 
stability of the device. It is composed of a distal titanium cap, embryo 
capsule, proximal titanium cap, silicon connector, intracervical stabiliser, 
reinforcement spring and a suture (Fig. 2).  
Model “S”:  ACVd1-S is used as a product reference for devices with 
intra-cervical stabilisation. This model was used to analyze gene expression 
with microarray technology. It consists of a distal titanium cap, proximal 
titanium cap, silicon connector, intrauterine stabiliser, suture, bumper, 
  34 
stabiliser sheath and intracervical sheath (Fig. 3). 
 
Figure 2: Model ACVd1-F Anecova device. 
 
Figure 3: Model ACVd-S Anecova device. 
The device was inserted into a standard embryo catheter provided by 
Anecova S.A by using transvaginal ultrasound. The embryologist first uses a 
placer wire to introduce the device into the catheter. Then, we use the wire to 
keep the device correctly located in the uterus while the catheter is removed 
from the uterine cavity. 
Plastic sterile tweezers provide by Anecova are used for both the 
assembly and disassembly of the device. Any manipulation was 
accomplished with these tweezers inside a vertical flow cabin. 
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4.3 STUDY DESIGN  
The women included in the study were volunteers from the ovum 
donation program aged 18 to 35 years without a history of hereditary 
diseases, predisposition to infection, or gynaecological disease such as 
endometriosis, polycystic ovary syndrome or hydrosalpinx. All women with 
known disease incompatible with clinical investigation, such as pelvic 
inflammatory disease, and patients with usual activity incompatible with this 
study, such as job schedules that do not allow time to go to medical visits, 
were excluded.  
For the first set of clinical experiments testing safety and stability, 
eleven volunteers were recruited. Two of them were excluded because one 
refused to participate and another could not be contacted. Thus, a total of 
nine patients participated in this part of the study.  
All patients were informed of the potential risks and burdens of the 
present clinical investigation prior to participating, such as the need to limit 
physical activities; irritation of the uterus, cervix or vagina; pain or bleeding; 
and infection (in the case of a sterility defect in the device and/or ancillary).  
The Anecova device was inserted immediately after oocyte retrieval and 
removed after 24 hours in five patients (Group 1) and after 6 days in the 
other three (Group 2). In one patient, the device was expelled before removal. 
Transvaginal ultrasound was performed every day of the device’s insertion. A 
diagnostic hysteroscopy was performed the day after the extraction of the 
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device. A questionnaire was given after the first ultrasound scan. Patients 
enrolled in Group 1 were prescribed bed rest during the test period. 
Because the volunteers were ovum donors, none of them had embryo 
transfer, and the endometrial effects of the device could be investigated.  
 
Figure 4: Schematic of the study design for clinical investigation. 
Second, the molecular study of the impact of the Anecova device on the 
endometrium was performed using a wide genomic approach in 20 ovum 
donors at day hCG +7. Patients were allocated into 4 groups (n=5 per group), 
in which the Anecova device was inserted for 18 hours, 3 days or 5 days after 
oocyte retrieval and then removed. The control group was composed of 
endometrial samples from ovum donors in whom the device was not inserted 
(Fig. 5). All patients underwent a routine stimulation protocol, and 
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endometrial biopsy was performed at hCG+7.  
 
 
 
 
 
 
Figure 5: Schematic of the study design for the endometrial study  
Finally, as an additional control, we decided to investigate the 
expression of key molecules for endometrial receptivity at the 
immunoreactive protein level in IUD users. We analysed the staining of 
progesterone receptors (PRA and PRB), prokineticin 1 (PROK-1), prokineticin 
1 receptor (PROK-R1) and leukaemia inhibitory factor (LIF).  
This study was approved by the ethics committee of the institutions 
where the endometrial biopsies were obtained (Génesis Unidad de Fertilidad 
y Reproducción, Caracas, Venezuela) and processed (Instituto Valenciano de 
Infertilidad, Valencia, Spain). Endometrial samples were obtained after 
written consent from patients. The clinical and laboratory work was 
performed at the Instituto Valenciano de Infertilidad and at the Queen’s 
Medical Research Institute, University of Edinburgh, United Kingdom. 
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Endometrial samples from three healthy, fertile volunteers (aged 23–39 
years, with a body mass index between 19 and 25 kg/m2) were obtained at 
LH+7 in month 1 during a natural cycle before IUD insertion; in month 2, 
the IUD was inserted; in month 3, the IUD was removed, and an endometrial 
sample was collected immediately after IUD removal; and a final sample was 
obtained at month 15. Therefore, endometrial biopsies were obtained at 
months 1, 3 and 15 in each woman at LH+7 as determined by assaying the 
LH surge in serum (Fig. 6).  
Overall, 10 biopsies (n=3 at months 1, 3 and 15, respectively (2 
biopsies from the patient A at month 15)) were obtained using a Pipelle 
catheter (Genetics, Namont-Achel, Belgium) under sterile conditions from the 
uterine fundus. Endometrial dating was performed using the Noyes criteria 
[90]. The inert IUD used in this study (Lippes Loop Intrauterine Double-S; 
Ortho Pharmaceutical Corp, Raritan, NJ) was chosen because it contains no 
hormones.   
 
 
 
Figure 6: Sc 
 
Figure 6:  Schematic of the study design and tissue collection schedule 
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4.4 CLINICAL PROCEDURE  
4.4.1 Ovarian Stimulation Protocol 
Recombinant FSH (rFSH) (Puregon, Organon) and GnRH antagonist 
Ganirelix (Orgalutran, Organon) were used for ovarian stimulation. In 
summary, a low-dose, monophasic-combined oral contraceptive pill (OCP) 
containing 150 mg of desogestrel and 30 mg of ethinylestradiol (Marvelon, 
Organon) was administered for 2 weeks starting on Day 1 of the pre-ART 
cycle. rFSH at a dose of 200 IU per day was started 5 days after 
discontinuation of the OCP. Ganirelix was initiated at a daily dose of 0.25 mg 
on Day 6 of the rFSH stimulation. Oocyte maturation was induced by the 
administration of 10,000 IU of hCG (Lepori 2500 UI 4 vials) when at least 
three follicles ≥17 mm diameter were present on ultrasound scan. Oocyte 
retrieval was carried out 36 h after hCG Lepori injection by vaginal 
ultrasound-guided puncture of ovarian follicles. 
4.4.2 Hysteroscopy  
For this study, a diagnostic hysteroscopy was performed on the day of 
the extraction of the device with a rigid 30-degree telescope whose outer 
diameter is 2, 9 mm. We used a telescope with a length of 30 cm (Kark Storz 
Endoscopy, Tuttlingen, Germany). 
The 30-degree telescope permitted rapid, dextrous evaluation of the 
anterior walls, posterior walls, and cornual recesses. Simply rotating the 
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telescope slightly to the right or left allowed a view of the tubal ostia. In 
comparison, the same view with a 0-degree scope requires angling the 
instrument to the left or right.  
The video system consisted of a TV monitor with S-VIDEO output 
(Sony LMD 2010 LCD), single-chip endoscopic video camera (Telecam SL, 
Karl Storz), and a camera control unit (Telecam SL, Karl Storz). 
To provide reasonable clearance for a 2, 9-mm telescope, we used a 
diagnostic sheet with an outer diameter (OD) of 4, 3 mm (Bettochi; Karl 
Storz). 
Our design consisted of a hollow tube, usually fitted with two 
stopcocks (right and left) for the installation of the distending medium. An 
operating channel mounted on the posterior or anterior surface and fitted 
with a stopcock feeds into the common channel (Luer-Lock, Karl Storz). The 
light source used was a light generator and a transmitting fiberoptic cable 
(Xenon NOVA 175 Karl Storz). It is usually called Cool Light because the 
infrared rays have been omitted from the light spectrum to prevent a 
warming effect. Hysteroscopy material was sterilised by autoclave.  
Distension was accomplished by insufflation with carbon dioxide (CO2) 
gas or by instillation of an electrolytic or non-electrolytic fluid. Fluids can be 
used for both diagnostic and operative procedures. Although CO2 is a useful 
distension media, it does not allow the clearing of blood and debris during 
the procedure. Complications may arise from gas embolism. For these 
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reasons, we used sterile physiological serum as the distension medium 
(Griffols, S.A). The system of distension used was a pressure bomb (Endomat 
Hamou Karl Storz). 
4.5 ENDOMETRIAL STUDY 
4.5.1 Wide Genomic Analysis.  
4.5.1.1 Tissue Collection 
Endometrial biopsies were collected with Pipelle catheters (Gynetics 
Medical Products N.V, #4164 probet, Belgium) under sterile conditions from 
the uterine fundus. One half of each sample was snap-frozen in liquid 
nitrogen and stored at -70ºC until further processing. 
4.5.1.2 RNA Isolation 
Total RNA was extracted using the Trizol method according to the 
protocol recommended by the manufacturer (Life Technologies, Inc., 
Gaithersburg, MD). In short, homogenised biopsies (1 ml Trizol reagent/75 
mg tissue) were incubated at room temperature for 5 min, chloroform (0.2 
volumes of Trizol) was added, and the samples were incubated for 2.5 min at 
room temperature. Thereafter, the samples were centrifuged for 15 min at 
12,000 g (4ºC). The aqueous phase was precipitated with an equal volume of 
2-propanol, stored in ice for 5 min and centrifuged for 30 min at 12,000 g 
(4ºC). The pellet was washed with 75% ethanol and dissolved in DEPC-
treated water. The integrity of the RNA samples (RNA quality control 
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procedure) was assessed using the 2100 bioanalyzer (Agilent Technologies, 
Madrid, Spain) by running an aliquot of the RNA samples on the RNA 6000 
Nano LabChip (Agilent Technologies, Madrid, Spain). All the samples had to 
obtain a RNA integrity number index (RIN) greater than 7 in order to be 
included in the analysis. 
 
4.5.1.3 Microarray Hybridisation Procedure 
All samples were hybridised onto the Whole Human Genome Oligo 
Microarray (Agilent Technologies, Madrid, Spain) encompassing more than 
44,000 human DNA probes. The protocols for sample preparation and 
hybridisation of the endometrial samples were adapted from the Agilent 
Technical Manual. Briefly, first-strand cDNA was transcribed from 1 mg of 
total RNA using T7-Oligo (dT) promotor primer. Samples were in vitro 
transcribed and Cy-3 labelled with the Quick-AMP labelling kit (Agilent 
Technologies, Madrid, Spain). The cRNA synthesis typically yielded between 
10 and 15 µg. Following a further clean-up round (QIAGEN, Barcelona, 
Spain), cDNA was fragmented into pieces ranging from 35 to 200 bases, 
which were confirmed using Agilent 2100 Bioanalyzer technology. 
Fragmented cRNA samples (1.65 µg) were hybridised onto chips through 17 
h of incubation at 65ºC with constant rotation; then, microarrays were 
washed in two washing buffers for 1 min each (Agilent Technologies, Madrid, 
Spain). Hybridised microarrays were scanned in an Axon 4100A scanner 
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(Molecular Devices, Sunnyvale, CA, USA) and data extracted with GenePix Pro 
6.0 software (Molecular Devices, Sunnyvale, CA, USA). 
4.5.1.4 Data Processing and Data Analysis  
GenePix Pro 6.0 software was used for array image analysis and the 
calculation of spot intensity measurements, which were used as raw data. 
Spot intensities (medians) without background subtraction were transformed 
to the log2 scale. Before quantile normalisation, data were represented in a 
box plot to check the data distribution, and abnormal microarray data were 
discarded. The replicates by gene symbol were merged, and the data were 
filtered to delete unknown sequences or probes without a gene description. 
The R statistical software system was used for these purposes and for 
downstream analysis [91].  
The gene expression profile was determined by comparing the 
experimental groups with the control group (2 by 2 comparisons) with non-
parametric tests. Two criteria were used to define genes that had altered 
mRNA abundance between the different sample sets: an absolute fold change 
of 2.0 or more and a corresponding fold change p-value lower than 0.05. 
4.5.1.5 Functional Analysis  
To detect activations or inactivations of biological functions or 
pathways, we used the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) [92], a gene set-based algorithm that detects significantly 
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represented functionally related genes in lists of genes ordered by differential 
expression. DAVID can search blocks of functionally related genes by 
different criteria, such as gene ontology terms or KEGG pathways.  
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) 
[93] represents the connexions among the differentially expressed genes. This 
bioinformatics tool provides information about a comprehensive and 
regulated group of protein associations for a large number of organisms. 
4.5.1.6 Clustering and Principal Components Analysis 
Expression data were normalised by Z-score. Hierarchical clustering 
was performed with MeV 4.2.02 software (http://www.tm4.org) [94] with a 
complete-linkage hierarchical clustering algorithm and visualised by the 
same software. Euclidean distance was chosen as the similarity measure. 
Principal components analysis (PCA) was performed using the MeV 
4.2.02 software. The data table of rows (genes) and columns (endometrial 
samples) was transposed and PCA was run to reduce the number of 
variables to two or three principal components representing the majority of 
the variability in the dataset. A two- or three-dimensional scatter plot was 
produced to visualise the differences between the sample sets (Control, 18 h, 
3 d and 5 d) based on each sample’s gene expression profile. 
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4.5.2 Immunohistochemical Study 
Immunohistochemical analysis of PRA and PRB. 
The method used for determining the progesterone receptor was the 
avidin-biotin immunohistochemistry method (ABC system, Dako Ltd., 
Cambridge, UK) with 3, 3´-diaminobenzidine as the chromagen. Secondary 
antibodies are conjugated to biotin and function as links between tissue-
bound primary antibodies and an avidin-biotin-peroxidase complex (Fig. 7). 
 
Figure 7: Avidin-Biotin Complex Method 
Whereas polyclonal antibodies are multiple antibodies produced by 
different types of immune cells that recognise the same antigen, monoclonal 
antibodies are derived from a single cell line (also referred to as a clone). The 
antibody chosen to detect the progesterone receptor in this experiment was a 
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monoclonal antibody.  
Solutions: 
-Sodium citrate autoclaved in the pressure cooker (PC): 1.8 L of 
deionised/distilled water + 200 ml of sodium citrate (0, 1 M, pH: 6.0). 
-Solution of hydrogen peroxide in distilled water. Peroxide (30% w/w 
SIGMA H1009). Final solution: 3%. 
-PBS: 1X concentration (P5368, SIGMA).  
-Serum block NGS/PBS/BSA mix (1 ml NGS/4 ml PBS/ 5% BSA): 1 ml 
of NGS + 4 ml of PBS + 5% BSA. As we prepared 5 ml, we weighed 0.5 g of 
BSA powder and mixed with 2.000 µl NGS and 8.000 µl of PBS for a final 
volume of 10 ml. NGS (Vector Laboratories, BIOSERA S1000, PBS (P5368, 
SIGMA) and BSA (A9647 SIGMA).  
-Vector Laboratories biotin/avidin blocking kit (Avidin blocking kit 
Vector Laboratories SP2061). 
-Primary Antibody: Mouse IgG monoclonal (Novocastra NCL-PGR A/B 
forms). We tested two dilutions (1:40 and 1:100), but we only obtained valid 
data for one of them (dilution 1:100). Concentration: 45 mg/l in serum block.  
-Negative control: Mouse IgG (SIGMA) at the same concentration: 
First: 9 µl of Mouse IgG sigma in 191 µl of block: This is the negative 
dilution. Second: 5 µl of the negative dilution in 195 µl of block: this is the 
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negative final.  
-For the positive control, we used samples from the mid-secretory 
phase and proliferative phase at a dilution of 1:40.  
-Secondary antibody: We prepared 1 ml of 1:200 dilution of 
biotinylated goat anti-mouse (Vector Labs BA9200), 1.600 µl of block + 8 µl 
of antibody. 
-PBST: 400 ml of PBS (PBS1 SIGMA)+ 200 µl of Tween (P9416 SIGMA)+ 
3.2 g of NaCl (S3014 SIGMA).  
-Tertiary antibody: RTU (ABC Elite Reagent), 3 drops each slide, for 30 
minutes at room temperature. 
-DAB (3, 3’-diaminobenzidinetrahydrochloride) (Vector Laboratories 
ImmPACT™ DAB Peroxidase substrate SK-4105): 2 drops into 2.000 µl of 
diluent and we put it into aluminium boil. 
-Mayer’s haematoxylin solution (Vector Laboratories).  
Procedure: 
Tissue fixation was accomplished with formalin (4%) (7040 JT Bake). 
The tissue fixation medium was replaced by wax, washed through a series of 
solutions with ethanol concentrations increasing to 100%(100986.1000, 
Merck, Spain), followed by xylene (Panreac Quimica S.A.U) and then hot wax 
(253211.1211, Panreac Quimica S.A.U). This process stabilises the tissue 
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(wax) to make cutting the sections easier. The tissue sections were cut at five 
microns and enclosed in cassettes (631-9614, VWR International Eurolab, 
S.L. Spain).  
Five-micrometre paraffin-embedded sections were dewaxed in xylene 
(Panreac Quimica S.A.U) twice for 5 minutes each and rehydrated in 
sequential solutions of ethanol absolute, 95º and 70º (818760 EMPLURA®, 
Merck, Spain), for 20 seconds in each. After that, slides were rinsed and kept 
in tap water. 
Antigen retrieval was performed by autoclaving sections for 5 minutes 
in boiling 0, 02 M sodium citrate (pH 6.0), and allowing 20 minutes to cool 
down. Afterwards, the slides were rinsed and kept in tap water. 
It is necessary to block the endogenous peroxidase activity with 3% 
(vol/vol) hydrogen peroxide in distilled water for 30 seconds at room 
temperature. Afterwards, we washed the slides twice with PBS, and then 
they were put in the Sequenza cover plates (Thermo-Shandon, 72110013). 
The rest of steps were performed with the slides in the Sequenza system.  
A Vector Laboratories biotin/avidin blocking kit was used for 15 
minutes at room temperature to block biotin and avidin binding sites. We 
added three drops to each slide. Then, we washed the slides twice in PBS 
and included 125 µl of serum block NGS/PBS/BSA mix on every slide. 
Sections were incubated with the primary antibody (NCL-Progesterone) 
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or with mouse IgG (negative control) overnight at 4ºC. Slides were washed 2 
times in PBST. 
Subsequently, they were incubated with biotinylated secondary 
antibodies. We put 125 µl of the dilution of goat anti-mouse antibody on 
each slide and waited for 30 minutes.  
Sections were again washed twice in PBST and incubated with the 
tertiary antibody RTU (ABC Elite Reagent). After that, we washed them in 
PBS and removed the excess Sequenza from the solution.   
The site of bound enzymes was identified by application of 3, 3-
diaminobenzidine in H2O2 to the samples for 5 minutes. Subsequently, they 
were washed with tap water for 5 minutes.  
We counterstained with nuclear solution of haematoxylin for 20 
minutes. Later, we washed the sections with tap water for 30 minutes and 
dehydrated them for 20 seconds with consecutive alcohols (70%, 80%, and 
95%) and absolute alcohol and for 5 seconds with xylene. To finish the 
fixation, a drop of Pertex on a cover slip was placed on the sample.  
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Immunohistochemical analysis of prokineticin 1 (PROK-
1) and the prokineticin 1 receptor (PROK-R1).  
We used a similar method for this analysis: the labelled streptavidin-
biotin (LSAB) method (Dako Ltd., Cambridge, UK). This method also utilises 
a biotinylated secondary antibody that links primary antibodies to a 
conjugated streptavidin peroxidase. In this case, the antibody chosen to 
detect the PROK-1 and PROK-R1 expression was a polyclonal antibody (Fig. 
8).  
 
Figure 8: Labelled Streptavidin-Biotin (LSAB) Method. 
Solutions:  
-Sodium citrate autoclaved in the pressure cooker (PC): 1.8 L of 
deionised/distilled water + 200 ml of sodium citrate (0, 1 M, pH: 6.0). 
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-Solution of 90 ml of methanol + 10 ml hydrogen peroxide.  
-TBS: 1.800 ml of water + 200 ml of TBS (10x) (stored at 4ºC), (T6664, 
SIGMA). 
-Serum block NGS/TBS/BSA mix (1 ml NGS/4 ml TBS/ 5% BSA): 1 ml 
of NGS + 4 ml of PBS + 5% BSA. We prepared 5 ml; we weighed 0.25 g of 
BSA powder and mixed with 1.000 µl NGS and 4.000 µl of TBS for a final 
volume of 5 ml. NGS (Vector Laboratories, BIOSERA S1000), TBS (T6664, 
SIGMA) and BSA (A9647 SIGMA).  
-Vector laboratories biotin/avidin blocking kit (Avidin blocking kit 
Vector Laboratories SP2061). 
-Primary antibody PROK-1: Rabbit polyclonal PROK-1 (Phoenix 
Pharmaceuticals H-023-59 Inc., Belmont, CA) at a dilution of 1:1000 in 
NGS/TBS/BSA mix.  
-Primary antibody PROK-1R-1: Rabbit polyclonal PROK-1R-1 (MBL; 
LS-A6684) (1:250). 
-Negative control: Rabbit IgG (Dako X0903) at an equivalent 
concentration to the antibody used (it was prepared with normal-goat serum 
(NGS) mix at a dilution of 1:1000 for PK1 and 1:250 for PKR1).  
-For the positive control, we used samples from the mid-secretory 
phase and proliferative phase at a dilution of 1:250.  
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-Secondary antibody (PROK-1 and PROK-R1): Biotinylated goat anti-
rabbit (Vector Labs BA 6000). We prepared 1 ml at 1:200 dilution (1000 µl of 
block + 5 µl of antibody). 
-Tertiary antibody (PROK-1 and PROK-R1): HRP conjugated 
streptavidin 1:1000 in TBS (K5001 Dako REAL™ Detection Systems 
(LSAB+)).  
-DAB (3, 3’-diaminobenzidinetrahydrochloride) (Vector Laboratories 
ImmPACT™ DAB Peroxidase substrate SK-4105): 2 drops into 2.000 µl of 
diluent and we put it into aluminium boil. 
-Mayer’s haematoxylin solution (Vector Laboratories).  
Procedure: 
Tissue fixation was accomplished with formalin (4%) (7040 JT Bake). 
The tissue fixation medium was replaced by wax and washed with ethanol 
solutions at a series of concentrations increasing to 100% (100986.1000, 
Merck, Spain), followed by xylene (Panreac Quimica S.A.U) and hot wax 
(253211.1211, Panreac Quimica S.A.U). This process stabilises the tissue 
(wax) to make cutting the sections easier. The tissue sections were cut at five 
microns and enclosed in cassettes (631-9614, VWR International Eurolab, 
S.L. Spain). 
Five-micrometre paraffin-embedded sections were dewaxed in xylene 
(Panreac Quimica S.A.U) twice for 5 minutes each and rehydrated in 
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sequential solutions of ethanol absolute, 95º and 70º (818760 EMPLURA®, 
Merck, Spain) for 20 seconds in each solution. Subsequently, the slides were 
rinsed and kept in tap water. 
Antigen retrieval was performed by autoclaving sections for 5 minutes 
in boiling 0, 02 M sodium citrate (pH 6.0) and then allowing 20 minutes for 
cool down. Later, the slides were again rinsed with tap water. 
We blocked the endogenous peroxidase activity with 3% (vol/vol) 
hydrogen peroxide in methanol for 30 seconds at room temperature. 
From this point, all washes were performed in a humidity chamber. 
First, we washed slides twice for 5 minutes each in TBS.  
As in the previous protocol, Vector Laboratories biotin/avidin blocking 
kit was used for 15 minutes at room temperature to block biotin and avidin 
binding sites. Then, we washed the slides twice in TBS. 
We added 50 µl of serum block NGS/TBS/BSA mix to every slide for 30 
minutes at room temperature.  
Sections were incubated with the primary antibody, rabbit antihuman 
polyclonal PROK-1 antibody (1:1000 in NGS mix) or rabbit polyclonal PROK-
1R-1 antibody (1:250 in NGS mix) overnight with a glass at 4º C. The slides 
were then washed twice for 5 minutes in TBS. 
Two negative controls were used at the same concentration of primary 
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antibody: 
-No primary antibody addition. 
-Rabbit IgG at an equivalent concentration to the antibody used 
(prepared with normal-goat serum (NGS) mix at a dilution of 1:1000 for PK1 
and 1:250 for PKR1. We added 100 µl of the dilution of goat anti-rabbit 
antibody to each slide and waited for 30 minutes. Afterwards, we washed the 
slides in TBS twice for 5 minutes each.  
Samples were incubated with the tertiary antibody-HRP conjugated 
streptavidin in TBS at a dilution of 1:1000 for 30 minutes at room 
temperature and then washed again in TBS twice for 5 minutes each. 
The sections were placed in DAB solution for 5 minutes and then 
washed with tap water for 5 minutes. To counterstain, we used a nuclear 
solution of haematoxylin for 20 minutes. Subsequently, we washed the 
sections with tap water for 30 minutes.  
We dehydrated the samples for 20 seconds with consecutive alcohols 
(70%, 80% and 95 %) and absolute alcohol and for 5 seconds with xylene. To 
finish the fixation, a drop of Pertex on a cover slip was placed on the sample.  
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Immunohistochemical analysis of leukaemia inhibitory 
factor (LIF)  
The same method (avidin-biotin immunohistochemistry method ABC) 
as in the first immunohistochemical experiment (PR) was used. The antibody 
was a polyclonal subtype. The specific solutions and the steps taken in the 
process follow: 
Solutions: 
-Sodium citrate autoclaved in the pressure cooker (PC): 1.8 L of 
deionised/distilled water + 200 ml of sodium citrate (0, 1 M, pH: 6.0). 
-Solution of hydrogen peroxide in distilled water. Peroxide (30% w/w 
SIGMA H1009). Final solution: 3%. 
-PBS: 1X concentration (P5368, SIGMA). 
-Serum blocker NHS/PBS/BSA mix (1 ml NGS/4 ml PBS/5% BSA): 1 
ml of NHS + 4 ml of PBS + 5% BSA. To prepare 5 ml, we weighed 0.5 g of 
BSA powder and mixed with 2.000 µl NHS and 8.000 µl of PBS for a final 
volume of 10 ml. NHS (Vector Laboratories, BIOSERA S2000), PBS (P5368, 
SIGMA) and BSA (A9647 SIGMA).  
-Vector laboratories biotin/avidin blocking kit (Avidin blocking kit 
Vector Laboratories SP2061). 
-Serum blocker: NHS (normal horse serum)/BSA/PBS at the same 
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concentration.  
-Primary antibody LIF: Goat polyclonal LIF antibody (AB-250-NAR&D 
Systems). We tested two concentrations: 1:50 and 1:25 in NHS/PBS/BSA 
mix. Negative control was goat IgG (R&D Systems, AB-108-C) at equivalent 
concentration. 
-For the positive control, we used samples from the mid-secretory 
phase and proliferative phase at dilutions of 1:50 and 1:25.  
-Secondary antibody: Biotinylated rabbit anti-goat (Vector Labs 
BA5000) at a dilution of 1:200. 
-Tertiary antibody: RTU (ABC Elite Reagent). 
-DAB (3, 3’-diaminobenzidinetrahydrochloride) (Vector Laboratories 
ImmPACT™ DAB Peroxidase substrate SK-4105): 2 drops into 2.000 µl of 
diluent and we put it into aluminium boil. 
-Mayer’s haematoxylin solution (Vector Laboratories).  
Procedure: 
Tissue fixation was accomplished with formalin (4%) (7040 JT Bake). 
The tissue fixation medium was replaced by wax, washed with a series of 
ethanol solutions at concentrations increasing to 100%  (100986.1000, 
Merck, Spain), followed by xylene (Panreac Quimica S.A.U) and then hot wax 
(253211.1211, Panreac Quimica S.A.U). This process stabilises the tissue 
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(wax) to make cutting the sections easier. The tissue sections were cut at five 
microns and enclosed in cassettes (631-9614, VWR International Eurolab, 
S.L. Spain). 
Five-micrometre paraffin-embedded sections were dewaxed in xylene 
(Panreac Quimica S.A.U) twice for 5 minutes each and rehydrated in 
sequential solutions of ethanol absolute, 95º and 70º (818760 EMPLURA®, 
Merck, Spain) for 20 seconds in each solution. Then, the samples were 
rinsed and kept in tap water. 
Antigen retrieval was performed by autoclaving sections for 5 minutes 
in boiling 0, 02 M sodium citrate (pH 6.0), and allowing 20 minutes to cool 
down. Then, the slides were again rinsed and kept in tap water. To block the 
endogenous peroxidase activity, we incubated slides with 3% (vol/vol) 
hydrogen peroxide in distilled water for 10 minutes at room temperature. 
From this point, all washes were performed in a humidity chamber. The first 
step was to wash the slides in PBS twice for 5 minutes each. Next, we 
blocked biotin and avidin binding sites with a Vector Laboratories 
biotin/avidin blocking kit for 15 minutes at room temperature. Then, we 
washed the slides twice in PBS. We added 50 µl of serum block 
NHS/TBS/BSA mix to every slide for 30 minutes at room temperature. 
Sections were incubated with the primary antibody, goat anti-human 
polyclonal LIF antibody (1:50 and 1:25 in NHS mix), and overnight at 4 º C. 
They were washed in TBS 2 times for 5 minutes. The negative control was 
goat IgG at an equivalent concentration of primary antibody. Then, we 
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washed slides twice for 5 minutes each in PBS. Subsequently, samples were 
incubated with biotinylated secondary rabbit anti-goat antibodies at a 
dilution of 1:200 and then allowed to rest for 30 minutes. Sections were 
again washed twice in PBS and incubated with the tertiary antibody RTU 
(ABC Elite Reagent). 
DAB solution was applied as the chromagen for 5 minutes; then, the 
slides were washed for 5 minutes with tap water. We counterstained with 
nuclear solution of haematoxylin for 20 minutes. Next, we washed the 
sections with tap water for 30 minutes. To dehydrate the samples, we 
incubated them for 20 seconds with consecutive alcohols (70%, 80%, and 
95%) and absolute alcohol and for 5 seconds with xylene. Finally, to 
complete the fixation, a drop of Pertex on a cover slip was placed on each 
sample.  
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5. RESULTS 
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5.1 SAFETY AND STABILITY STUDY.   
The patients were asked to report any feelings of discomfort after 
insertion of the device. In addition, each patient was extensively monitored. 
In all cases, the device was introduced under ultrasound monitoring without 
any complications. It was subsequently removed after 24 hours in five of the 
patients (group 1) and after 6 days in the other 3 (group 2). 
 
 
 
 
 
 
 
Figure 9: Anecova device retrieval after 6 days inside the endometrial cavity. 
Three of nine patients (3/9) had the device displaced to the isthmus, 
and it was observed in the internal os. When the device was removed, we did 
not observe any alteration in the uterine cavity. In one case the device was 
expelled on the day of insertion. Only one of the patients suffered symptoms 
such as sweating and dizziness, but this woman was reported to be prone to 
having fainting fits and low blood pressure. Another patient reported 
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pain in the left ovary that was not associated with the presence of the device.   
During the hysteroscopic examination, we noticed an isthmical 
stenosis in one patient close to the area of the caesarean section with a 
normal cavity. This patient showed a small inflammatory reaction in the 
vessels located in the left posterior side of the endometrial cavity that was 
probably due to the insertion of the device.  
 
Figure 10: Picture of endometrial cavity taken during hysteroscopy. A slight Anecova 
device fingerprint is observed in the left endometrial side pointing towards the tubal 
ostium (arrow). 
In another patient, we observed focal hyperaemia during the extraction 
process. Three days earlier, this patient had suffered abdominal pain and 
abdominal distension.  
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Figure 11: Picture of endometrial cavity taken during hysteroscopy. Slight hyperaemia 
extended over the endometrium. 
None of the patients felt serious pain, sickness, bleeding or subjective 
perception of feeling the device. In addition, all patients reported normal 
menstruation in the next cycle after removal of the device.  
5.2 Wide Genomic Analysis. 
5.2.1 RNA Quality 
 RNA integrity was based on a procedure that involves the separation 
of RNA into differently sized fragments by capillary electrophoresis molecular 
sieving, with results shown on an electropherogram. The program calculates 
an RNA integrity number (RIN) index. All samples obtained a RIN greater 
than 7.5, except sample ANE-11 with a RIN of 6.7, which was excluded from 
the analysis (Table 1). 
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Table 1: The RIN data correspond to the RNA integrity. Sample ANE-11, with a RIN of 
6.7, was excluded from the analysis. 
5.2.2 Identification of Altered Gene Expression 
In the log2 transformation, we detected outliers in the low-RIN sample 
and two more samples (ANE-9, ANE-10). These two samples were also 
excluded (Fig. 12). In statistics, an outlier is an observation that is 
numerically distant from the rest of the data. 
 
Figure 12: Box-plot representation of the log2-transformed median for all samples; 
black arrows indicate outliers.  
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The final number of samples in the analysis was 17. We show the normalised 
data in Figure 13.  
 
Figure 13. Box-plot representation of the log2-transformed medians for 17 samples 
(excluding ANE-9, ANE-10 and ANE-11). Even without normalising the box-plots are 
quite similar. Box-plot representation of the normalised data.  
  65 
To evaluate the effect of the Anecova device on the gene expression 
pattern of the endometrium, the data were analysed by comparing each 
experimental group (18 h, 3 d or 5 d) with the control group (Table 2, annex). 
The number of dysregulated genes in each group is indicated in Table 3. 
 
Table 3: Comparison of samples (n=5) exposed to the device for 18 hours, 3 days or 5 
days against the control samples (women who were not exposed to the device, whose 
biopsy was taken on day 5 after follicular punction). This table only summarises the 
number of probes with an upward or downward fold change greater than 2 and 
statistical significance lower than 0.05.  
In the comparison between endometrial gene expression with device 
insertion for any period of time (18 h, 3 d and 5 d) versus control samples, 
the number of dysregulated DNA probes was 10 (7 up- and 3 down-
regulated), but not all of them were known genes (Table 4).  
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Table 4: Comparison between the samples exposed to the device vs. controls. 
Summary of the number of probes with a fold-change larger than 2 or smaller than -2 
and a statistical significance lower than 0.05 in all mentioned comparisons. The genes 
are named according to the database of the National Center for Biotechnology 
Information (NCBI). 
Only two genes were dysregulated in all study groups. Four genes 
coincided between the 3-day and 5-day groups. Finally, four different genes 
were identified that coincided between the 18-hour and 3-day groups (Fig. 
14).  
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Figure 14: This diagram shows the number of dysregulated genes that coincided in the 
three groups (device inside uterus for 18 hours, 3 days or 5 days vs. control samples). 
When the sequences were analysed to determine the relations among 
them (STRING), there was no statistical relationship with any gene ontology 
term. The DAVID Database was also used to study the expression of these 
sequences. We learned that only the endometrium samples from the 3-day 
group showed more differences than the control samples did. 
Thirty-three of the dysregulated genes with a p-value lower than 0.05 
were related to multicellular organismal processes; 4 had a relationship with 
metabolic processes (oxygen and reactive oxygen species); 17 had transporter 
activity; and 3 were related to gamma-glutamyltransferase activity and 5 
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were related to arachidonic-acid metabolism. We also noticed that four 
dysregulated genes in the 3-day insertion group had a direct relationship 
with glutathione metabolism. 
5.2.3 Clustering 
An unsupervised hierarchical clustering was performed for the 17 
endometrial biopsies. This analysis revealed that endometrial samples from 
subjects with the Anecova device, regardless of their duration of exposure, 
and from controls, clustered irrespective of their origin, do not show 
differences in the global gene expression profiles (Fig. 15).  
 
Figure 15: Cluster analysis revealed no differences in the global gene expression 
profiles among specimens. 
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5.2.4 PCA (Principal Components Analysis) 
When PCA was applied to data, samples with similar trends in their 
gene expression profiles tended to cluster close together in the plot. In this 
case, the samples from each group do not have similar trends in their 
expression profiles and do not cluster close together, suggesting no genomic 
impact of the device on the endometrium (Fig. 16).  
 
Figure 16: PCA demonstrates the variability among groups, suggesting no identifiable 
endometrial effect.  
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5.3 IMMUNOHISTOCHEMISTRY STUDY 
5.3.1 Scoring System and Summary Slides Data 
The immunostaining intensity of all tissue sections was scored on a 
four-point scale, where (-) = no staining, (+/-) = slightly positive, (+) = weakly 
positive, and (++) = strongly positive. The score depended on the intensity of 
staining expressed by most of the cells in each chosen area. In each area (at 
a scale of 100X or 50X magnification), the percentage of stained cells at each 
scale was approximated by eye and by the same observer (Manuel 
Fernández-Sánchez) to avoid interobserver variability. 
Immunohistochemical Localisation of Progesterone Receptors 
(PRA+PRB)  
As expected, in the endometrial samples analysed from the three 
patients at day LH+7, we observed a weak staining in some nuclei of stromal 
cells and a very weak stain in glands. Staining was practically negative 
before, during and after IUD insertion (Fig. 17). The data generated are 
summarised in Table 5.  
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Figure 17: Immunohistochemical analysis of paraffin-embedded sections from patients 
A and B. Temporal expression and localisation of progesterone receptors (PRA and 
PRB) was detected at the mid-secretory phase. Endometrial biopsies were obtained 
before, during and after IUD placement, respectively, at months 1, 3 and 15. The 
positive control (endometrial sample at the mid-secretory phase) presents strong 
labelling, whereas no staining was detected in the negative control (Mouse IgG) (D). For 
antibody dilutions, see the Materials and Methods section. 
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Table 5: Designations of – (negative), +/- (weakly positive), ++ (strongly positive) and 0 
(invaluable result) indicate the relative intensities of the signals. Patients are 
designated as samples A, B and C. P (proliferative phase) and MS (mid-secretory phase) 
are positive controls. Mouse IgG is the negative control. 
Our results indicate that immunoreactive PRs were already down-
regulated at LH+7, and this status was not modified in the presence or 
absence of the IUD. 
Significant differences were not found in patient C’s samples. In 
addition, comparison of these results was not possible because no valid 
results were obtained for patient C at month 3 (figure not shown).   
Immunohistochemical localisation of PROK-1 and PROK-R1 
Prokineticin 1 (PROK-1) 
Immunohistochemical staining for PROK-1 was detected in the 
cytoplasm of glands, nuclei and cytoplasm of stromal cells, with 
heterogeneity among patients. As can be observed in Figure 18, a 
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slight decrease in stroma and glandular staining intensity was observed in 
the functional layer after exposure to the device compared with the pre-IUD 
samples in patient A. No staining was detected in vessels in the samples after 
IUD exposure, and few differences were found in the epithelial surface.  
The intensity of immunostaining in patient B was globally very similar 
in the 3 biopsies, (before, during and after IUD placement); except for 
stronger staining in the pre-IUD epithelial surface (Fig. 18). 
In patient C, there were no differences in the immunostaining (figure 
not shown), although we could not obtain valid results for samples at month 
3.  
Positive controls were all completely positive in samples at both the 
mid-secretory and proliferative phases. A slight expression of PROK-1 in the 
negative control was detected by using rabbit IgG (Fig. 18). However, there 
was a clear reduction in staining of this control compared with the 
experimental samples.    
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Figure 18: Immunohistochemical analysis of paraffin-embedded endometrium sections 
of patients A and B. Temporal expression and localisation of prokineticin 1 (PROK-1) 
was detected at the mid-secretory phase. Staining decreased in glands and stroma as 
the duration of IUD exposure increased (magnification 50 µm).  
We show the results of expression of PROK-1 in the following table 
(Table 6). 
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Table 6: Designations of – (negative), +/- (weakly positive), ++ (strongly positive) and 0 
(invaluable result) indicate the relative intensities of the signals. Patients are 
designated as samples A, B and C. P (proliferative phase) and MS (mid-secretory phase) 
are positive controls. We used two negative controls. In one of them, we did not use 
primary antibody (Neg no Ab), and in the other control we used rabbit IgG.   
 
Prokineticin 1 Receptor (PROK-R1) 
Glandular cytoplasm, nuclei and cytoplasm of stromal cells also 
displayed immunoreactivity for PROK-R1. A slight decrease in the stroma 
and glandular staining was detected in the samples after IUD insertion 
compared with samples taken before and during IUD placement in the same 
patients (Fig. 19). 
Neither rabbit IgG nor the negative control with no primary antibody 
showed staining, whereas both positive controls were completely positive.  
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Figure 19: Immunohistochemical analysis of paraffin-embedded endometrium sections 
from patients A and B. Temporal expression and localisation of the prokineticin 1 
receptor (PROK-R1) was detected at the mid-secretory phase. Endometrial biopsies 
were obtained before, during and after IUD placement, respectively at months 1 
(A1/B1), 3 (A2/B2) and 15 (A3/B3). The result of the negative control for PROK-R1 
using rabbit IgG is completely negative. For antibody dilutions, see the Materials and 
Methods section. 
 
The summary of the results is presented in the table below (Table 7): 
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Table 7: Designations of – (negative), + (weakly positive), ++ (strongly positive) and 0 
(invaluable result) indicate the relative intensities of the signals.  
Immunohistochemical localisation of LIF.  
To investigate the potential endometrial regulation of LIF by the IUD, 
we tested two concentrations (1:50 and 1:25); the results shown correspond 
to the 1:25 dilution. The staining pattern was localised in the glandular 
cytoplasm and nuclei of stroma cells. Stroma staining decreased at month 3, 
but at month 15 the staining was as high as in the samples before IUD 
insertion. 
Among the differences found, we can mention decreased staining in 
vessels and on the epithelial surface during (month 3) and after IUD 
placement (month 15) with respect to the biopsies before IUD insertion 
(month 1). The signal in the negative control was slightly positive, probably 
because the antibody used may be non-specific; nevertheless, there was a 
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clear reduction in staining of this control compared with the study samples 
(Fig. 20). 
 
Figure 20: Immunohistochemical analysis of paraffin-embedded endometrium sections 
from patients A and B. Temporal expression and localisation of leukaemia inhibitory 
factor (LIF) was detected at the mid-secretory phase. Endometrial biopsies were 
obtained before, during and after IUD placement, respectively, at months 1, 3 and 15. 
Staining decreased in the stroma at month 3 but increased again in samples after IUD 
exposure at month 15. For antibody dilutions, see the Materials and Methods section. 
We present the summary of results for LIF in Table 8. 
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Table 8: Designations of – (negative), + (weakly positive), ++ (strongly positive) and 0 
(invaluable result) indicate the relative intensities of the signals. Patients are 
designated as samples A, B and C. P (proliferative phase) and MS (mid-secretory phase) 
are positive controls. The negative control used is Goat IgG. 
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6. DISCUSSION 
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This study demonstrated the clinical safety, stability and tolerance of 
the implantation and retrieval of the unloaded Anecova device in the uterus 
for a period of up to 6 days. Furthermore, we investigated the genomic 
impact of the device on the endometrium, compared with control 
endometrium without implantation of the device, at day hCG+7 in ovum 
donors undergoing IVF in whom this device was inserted for one, three or five 
days prior to endometrial biopsy.  
The hysteroscopic evaluation in volunteer oocyte donors who had the 
Anecova device implanted for 24 hours or 6 days did not show relevant 
macroscopic differences. There were no signs of inflammatory changes such 
as hyperaemia, strawberry pattern, or hypervascularisation [95]. This 
absence of disorders is reassuring from a macroscopic point of view. In 
addition, our findings make a useful contribution to future studies, including 
improvements in the device’s design. Improvements will be necessary 
because the device was displaced further into the isthmus in three patients, 
and in another patient it was displaced the day after its insertion. These 
findings suggest that a sterile tampon should be placed into the vagina to 
maintain the placement of the device in future studies. 
Our data on the effect of the new Anecova device on the endometrium 
revealed no differences in the global gene expression profiles between 
specimens, regardless of the duration of insertion. Our patients were 
allocated into 4 groups (n=5 per group), and the Anecova device was inserted 
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for 18 hours, 3 days or 5 days, or not at all as a control, after oocyte 
retrieval.  
Few dysregulated genes were  observed in the 3-day group that were 
related to specific cellular functions, such as metabolic processes, gamma-
glutamyltransferase activity, arachidonic-acid metabolism and glutathione 
metabolism. Gamma-glutamyltransferase is related to glutathione 
metabolism by transferring the glutamylmoiety to a variety of acceptor 
molecules [96]. The arachidonic-acid metabolism produces signalling 
molecules called eicosanoids, which include prostaglandins, leukotrienes 
and lipoxins [97]. All of these molecules control key cellular processes, 
including cell activation, metabolism, migration, proliferation and death [98, 
99]. 
Among glutathione’s functions are detoxification, antioxidant defence, 
maintenance of thiol status involved in cell death and modulation of cell 
proliferation [100]. In addition, the intracellular antioxidant system based on 
glutathione could be involved in the pathogenesis of endometriosis [101].  
These findings suggest a possible inflammatory reaction of the 
endometrium to the presence of a foreign body, but no clear differences were 
found after clustering or PCA analysis.  
To test the impact of this new device on the endometrium compared 
with a regular IUD, we conducted an immunohistochemistry control study 
analysing three distinct molecules: PRs, PROK-1 and PROK-1R, that are key 
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molecules for endometrial receptivity.  
In the analysis of progesterone receptors (PR), we chose an antibody 
that binds to both receptors (PRA and PRB) according to previously 
published studies [102]. Our findings in control samples during the 
proliferative phase are consistent with those observed by Mote’s team some 
years ago [72]. Levels of PR proteins were increased in glands and stroma, 
probably because of estrogen stimulation in the glandular epithelium during 
the proliferative phase. 
Our results do not show a significant change in the expression of PR 
due to the IUD either during its use or one year after its removal. The 
expression of PR was very similar across the three insertion durations in 
both glands and stroma cells, showing very weak staining.  
Other authors, such as Critchley and Zhu, determined the endometrial 
expression of PR (both receptors) in women who had a levonorgestrel-
releasing IUD inserted for a total period of 12–15 months [103, 104]. In both 
studies, PRA and PRB immunoreactivity showed a statistically significant 
decrease of PR in the endometrium of users of this type of IUD compared 
with biopsies prior to insertion of the IUD, but this decrease was neither 
uniform nor cell-specific.   
Our results cannot be compared with theirs for three reasons. First, 
their data were pooled regardless of cycle phase (in the case of Critchley) or 
the samples were collected in the proliferative phase (in Zhu’s study). 
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Second, the total time of exposure to the device was approximately one year, 
whereas in our study the device was inside the uterus for only one month. 
Finally, both Critchley and Zhu used an IUD loaded with levonorgestrel. This 
type of IUD can have side effects such as intermenstrual spotting and 
amenorrhoea, which could cause problems for the patients. The Lippes Loop 
Intrauterine Double-S, which we used in this work, is not associated with 
any hormone that could modify the gene expression profile, so it is 
considered a quite inert device. This feature makes it a good control for the 
Anecova system.    
According to several experiments, the interaction between PROK-1 and 
PROK-R1 regulates the expression of crucial genes related to the 
implantation process [105]. Nevertheless, we decided to study PROK-1 
instead of PROK-2 because of some results previously reported, such as 
those obtained by Battersby and collaborators [52]. They hold that PROK-1 
can have a regulatory role, whereas PROK-2 may have a permissive function 
in the uterus. This idea is supported by their PCR data, which indicate a 
temporal variation in the expression of PROK-1 (high in the secretory phase 
of the menstrual cycle), but not PROK-2. 
Our results for PROK-1 indicate a slight variability among patients. 
Although, for PROK-R1, we detected a slight decrease in stroma and 
glandular staining after IUD insertion, we cannot affirm that PROK-1 and 
PROK-R1 expression is affected by the presence of this type of IUD.  
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The results obtained from this study are not in total agreement with 
those reported by Battery’s team [52]. They observed a greater expression of 
PROK-1 during the mid-secretory phase compared with the proliferative 
phase. This effect is probably mediated via paracrine mechanisms of 
progesterone, as reported by Kurita and colleagues in in vitro studies in mice 
[106]. The exact reasons for the differences between these studies and our 
own are not clear, although they could be attributed to differences in 
experimental conditions. 
We obtained unexpected results for LIF. The commercial antibodies 
available for this factor are not always comparable, and the purchased 
antibodies are often non-specific. Therefore, we cannot draw proper 
conclusions from this experiment.  
The global gene expression profile of the endometrium during the 
window of implantation in the presence or absence of an inert IUD has been 
described previously [89]. Unlike our results for the endometrial gene 
expression of the Anecova device, previous research has found significant 
differences in gene expression due to the presence of this foreign body. The 
collection of biopsies followed the same protocol as in our study, and the 
type of IUD used was also the same. Month 1 was a natural cycle before IUD 
insertion; in month 2, the IUD was inserted; and in month 3, the IUD was 
removed. The samples were obtained at months 1, 3, 5, and 15.  
Biopsies obtained at month 3 showed 78 up-regulated and 69 down-
regulated transcripts. When they compared the biopsies collected 
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after IUD removal with those obtained in the natural cycle, they found 
interesting results: Only five genes restored their normal expression two 
months after IUD removal whereas one year later most of the genes (80%) 
had recovered their normal expression [89]. 
They identified genes related to apoptosis, ion transporters, 
immunomodulators, secretory proteins, signal transduction, membrane 
proteins, and transcription factors. Among these dysregulated genes, they 
obtained gene expression changes for LIF. This factor, which is usually up-
regulated at the time of implantation, was reported to have decreased 
expression at month 5, although it was restored one year after IUD removal. 
These findings are consistent with our results for LIF obtained from the 
immunohistochemistry study.  
The hysteroscopic evaluation in volunteer oocyte donors who had the 
Anecova device implanted for 24 hours or 6 days did not show relevant 
macroscopic differences. In addition, our findings will contribute to 
subsequent studies and to improvements in the device’s design. In three 
patients, the device displaced further into the isthmus, and in another 
patient, it was expelled the day after its insertion. Therefore, we suggest 
using a sterile tampon placed into the vagina to keep the device in place in 
future studies. 
After ruling out a possible endometrial effect, a pilot study of in vivo 
embryo development was carried out [107]. The results of this trial are not 
addressed in this thesis. These results demonstrate that the 
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embryos introduced using this device divided normally and were 
chromosomally normal. Furthermore, it was possible to achieve healthy live 
births after the transient presence of an inert foreign device in the uterus. 
This was the first work describing a novel in utero culture system that 
allowed direct communication between the embryos and the maternal 
endometrium.  
One outstanding question is, then, why the Anecova device did not 
have the same contraceptive effect as the IUDs. One of the potential answers 
could be that the non-allergenic components of the device (mainly silicone, 
titanium and suture) prevent the effects of the different materials that are 
used in the IUDs. 
Another possible explanation of the safety of the Anecova device may 
be the period of time that it remains inside the uterus. In this case, we 
studied the gene expression changes caused by the insertion of the device for 
a maximum of 5 days, whereas an IUD can remain inside the uterus for 
months or years.  
Finally, another potential reason for the different effect of the Anecova 
device is the place of insertion. An IUD must be inserted at the fundus of the 
uterus, whereas the new system is located in the lower uterine segment. 
Therefore, it remains to be determined whether different parts of 
endometrium have distinct gene modulation patterns in response to a similar 
stimulus. 
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Although in vivo embryo development studies using this device have 
already been reported, further studies will clearly be required to confirm the 
functionality of this new in vivo culture system.  
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7. CONCLUSIONS 
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1. The stability of the IUD was acceptable, except in two patients in 
whom it was displaced further into the isthmus. These findings are 
useful for directing improvements to the device’s design. 
 2. The hysteroscopic evaluation in volunteers who had the IUD 
inserted for 24 hours or 6 days did not show relevant macroscopic 
findings. 
3. Wide genomic analysis of the endometrial samples obtained from 
subjects with the IUD inserted for varying durations reveals no 
significant differences compared with the controls. 
4. Our results do not show a significant change in the expression of 
PR, PROK-1 or PROK-R1. 
5. In summary, we demonstrated the safety and tolerance of the 
insertion and retrieval of the IUD and the absence of relevant 
endometrial genetic impact of this unloaded device in the uterus for up 
to 6 days.  
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8. ANNEXES 
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TABLE 2.1: Device (18 h) Versus Control 
 
Table 2.1 (Results: 4.2.2): This table shows the 10 up- and 6 down-regulated DNA 
probes in samples obtained after insertion of the device for 18 h compared with the 
control samples. The table summarises the number of the probes with a fold change 
larger than 2 or smaller than -2 and a statistical significance lower than 0.05 in all of 
the mentioned comparisons. The genes are named according to the National Center 
for Biotechnology Information (NCBI) database. 
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TABLE 2.2: Device (3 days) Versus Control 
Table 2.2.A: 
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Table 2.2.B: 
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Tables 2.2A/2.2B (Results: 4.2.2): These tables show the data of samples obtained after 
insertion of the device for 3 days compared with the control samples and summarises the 
number of probes with a fold change greater than 2 (Table 2.2.A) or less than -2 (Table 2.2.B) 
and statistical significance lower than 0.05. The genes are named according to the database of 
the National Center for Biotechnology Information (NCBI). 
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TABLE 2.3: Device (5 days) Versus Control 
 
Tables 2.3 (Results: 4.2.2): These tables show the data of samples obtained after 
insertion of the device for 5 days compared with the control samples and summarises 
the number of probes with a fold change greater than 2 (Table 2.3.A) or less than -2 
(Table 2.3.B) and a statistical significance lower than 0.05. The genes are named 
according to the database of the National Center for Biotechnology Information (NCBI). 
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